Franc¸ois Raffi

Q: What Schools Are Affiliated With Franc¸ois Raffi

Franc¸ois Raffi is affiliated with the following schools: University of Nantes

Franc¸ois Raffi's AcademicInfluence.com Rankings

Franc¸ois Raffi

Philosophy

#9112

World Rank

#12621

Historical Rank

Logic

#6105

World Rank

#7588

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Franc¸ois Raffi Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Franc¸ois Raffi's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. (2015) (1182)
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study (2004) (734)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study (2019) (512)
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study (2019) (512)
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (2013) (470)
Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. (2008) (440)
Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. (2003) (422)
HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population (2007) (421)
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team). (2000) (407)
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults (2008) (393)
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. (2008) (353)
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (2019) (343)
Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. (2002) (335)
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. (2013) (333)
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. (2001) (294)
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 (2004) (282)
Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. (2002) (266)
Self-Reported Symptoms After Initiation of a Protease Inhibitor in HIV-Infected Patients and Their Impact on Adherence to HAART (2001) (241)
Response to combination antiretroviral therapy: variation by age (2008) (230)
Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment (2012) (226)
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team. (1998) (213)
The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort (2001) (208)
Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome: Efficacy of long-term continuous therapy (1988) (205)
Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors (2020) (202)
Opportunistic infections occurring during highly active antiretroviral treatment (1998) (194)
Endocrine function in 98 HIV-infected patients: a prospective study. (1991) (192)
Utility of hyposmia and hypogeusia for the diagnosis of COVID-19 (2020) (191)
Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen (2002) (175)
Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial (2014) (173)
CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE (2012) (171)
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial (2021) (168)
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial (2021) (167)
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. (2004) (164)
Sustained bacteremia in 26 patients with a permanent endocardial pacemaker: assessment of wire removal. (1993) (140)
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. (2014) (134)
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. (2016) (133)
Factors Associated With Nonadherence to Highly Active Antiretroviral Therapy: A 5-Year Follow-Up Analysis With Correction for the Bias Induced by Missing Data in the Treatment Maintenance Phase (2006) (124)
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients (2000) (123)
Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. (2000) (122)
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort (2021) (121)
Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. (2009) (121)
Pasteurella multocida bacteremia: report of thirteen cases over twelve years and review of the literature. (1987) (121)
Health-related quality of life and patient–provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment (2004) (117)
Detection of Microsporidia and Identification of Enterocytozoon bieneusi in Surface Water by Filtration Followed by Specific PCR. (1997) (116)
Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults (2009) (116)
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults (2009) (115)
Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. (2017) (114)
Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen. (2002) (113)
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. (2002) (112)
Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study (2002) (110)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. (2013) (108)
European Bat Lyssavirus Transmission among Cats, Europe (2009) (95)
A Nucleoside- and Ritonavir-Sparing Regimen Containing Atazanavir Plus Raltegravir in Antiretroviral Treatment-Naïve HIV-Infected Patients: SPARTAN Study Results (2012) (92)
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens. (2001) (92)
High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. (2012) (87)
Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults (2007) (84)
A prospective study of criteria for the diagnosis of toxoplasmic encephalitis in 186 AIDS patients (1997) (83)
Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. (2003) (82)
Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial. (1999) (79)
Determination of atazanavir and other antiretroviral drugs (indinavir, amprenavir, nelfinavir and its active metabolite M8, saquinavir, ritonavir, lopinavir, nevirapine and efavirenz) plasma levels by high performance liquid chromatography with UV detection. (2004) (78)
Reliability of the bronchoscopic protected catheter brush in intubated and ventilated patients. (1985) (78)
Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora. (2001) (78)
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations (2004) (72)
Prevalence and Risk Factors of Sleep Disturbance in a Large HIV-Infected Adult Population (2016) (71)
Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. (2015) (70)
Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8) (2007) (69)
Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. (2013) (67)
Long‐term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs (2007) (66)
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults (2017) (64)
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL) (2018) (63)
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial. (2015) (63)
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. (2009) (62)
A liquid chromatography-tandem mass spectrometry assay for quantification of nevirapine, indinavir, atazanavir, amprenavir, saquinavir, ritonavir, lopinavir, efavirenz, tipranavir, darunavir and maraviroc in the plasma of patients infected with HIV. (2009) (61)
Potential efficacy of fumagillin in intestinal microsporidiosis due to Enterocytozoon bieneusi in patients with HIV infection: results of a drug screening study (1997) (60)
European Bat Lyssavirus Transmission among Cats (2009) (60)
Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. Study Group. (1995) (60)
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy (2009) (60)
Candida endocarditis: role of new antifungal agents (2009) (59)
Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk (2017) (56)
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials (2015) (54)
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 (2021) (52)
Low CD4/CD8 Ratio Is Associated with Non AIDS-Defining Cancers in Patients on Antiretroviral Therapy: ANRS CO8 (Aproco/Copilote) Prospective Cohort Study (2016) (52)
Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study) (2002) (52)
Hepatitis C virus incidence in HIV‐infected and in preexposure prophylaxis (PrEP)‐using men having sex with men (2018) (50)
The Virgo Study: Nevirapine, Didanosine and Stavudine Combination Therapy in Antiretroviral-Naive HIV-1-Infected Adults (1999) (49)
Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from an Inter-Cohort Analysis (2006) (49)
Incidence of new hepatitis C virus infection is still increasing in French MSM living with HIV (2018) (49)
Six-Week Randomized Controlled Trial To Compare the Tolerabilities, Pharmacokinetics, and Antiviral Activities of GW433908 and Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients (2004) (49)
Prolonged hepatitis A infection in an HIV‐1 seropositive patient (2002) (48)
Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy. (2004) (48)
Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. (2000) (48)
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials. (2006) (45)
Structured Treatment Interruptions in Primary HIV-1 Infection: The ANRS 100 PRIMSTOP Trial (2005) (45)
Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients (2007) (45)
Uncontrolled Viral Replication as a Risk Factor for Non-AIDS Severe Clinical Events in HIV-Infected Patients on Long-Term Antiretroviral Therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study (2009) (45)
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. (2011) (45)
Has the time come to abandon efavirenz for first-line antiretroviral therapy? (2014) (45)
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients (2006) (45)
Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients (2018) (45)
Lopinavir pharmacokinetics in COVID-19 patients (2020) (44)
Long‐term (96‐week) follow‐up of antiretroviral‐naïve HIV‐infected patients treated with first‐line lopinavir/ritonavir monotherapy in the MONARK trial * (2010) (43)
Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8). (2007) (42)
What if HIV were unable to develop resistance against a new therapeutic agent? (2013) (41)
High Risk Features Contrast With Favorable Outcomes in HIV-associated Hodgkin Lymphoma in the Modern cART Era, ANRS CO16 LYMPHOVIR Cohort. (2015) (41)
Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smokers (2016) (41)
Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV‐Infected Patients Initiating Protease Inhibitors (2001) (41)
A Comparison of the Steady‐State Pharmacokinetics and Safety of Abacavir, Lamivudine, and Zidovudine Taken as a Triple Combination Tablet and as Abacavir plus a Lamivudine‐Zidovudine Double Combination Tablet by HIV‐1‐Infected Adults (2001) (41)
Time perspective and quality of life among HIV-infected patients in the context of HAART (2007) (40)
Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity. (2015) (40)
Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population. (2001) (40)
Amphotericin B in a lipid emulsion for the treatment of cryptococcal meningitis in AIDS patients. (1996) (40)
Dolutegravir: Clinical and Laboratory Safety in Integrase Inhibitor–Naive Patients (2014) (39)
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment‐naïve HIV‐1‐infected patients (2011) (39)
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors (2004) (38)
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather* (2015) (38)
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. (2008) (38)
Polymorphism in Gag Gene Cleavage Sites of HIV-1 Non-B Subtype and Virological Outcome of a First-Line Lopinavir/Ritonavir Single Drug Regimen (2011) (38)
Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV‐infected patients started on a protease inhibitor‐containing regimen (2006) (38)
Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French National Healthcare Insurance Database. (2015) (36)
Low-dose methotrexate for the treatment of patients with large granular lymphocyte leukemia associated with rheumatoid arthritis. (2000) (36)
Adherence to Antiretroviral Therapy and Outcomes in HIV-Infected Patients Enrolled in An Induction/Maintenance Randomized Trial (2001) (36)
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. (2019) (36)
Metabolic syndrome in French HIV-infected patients: prevalence and predictive factors after 3 years of antiretroviral therapy. (2012) (35)
Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study (2019) (34)
Efficacy and Tolerability of a Nucleoside Reverse Transcriptase Inhibitor-Sparing Combination of Lopinavir/Ritonavir and Efavirenz in HIV-1-Infected Patients (2005) (33)
Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy. (1988) (33)
Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. (2010) (33)
An outbreak of airborne tularaemia in France, August 2004. (2006) (32)
Improving diagnostic criteria for Propionibacterium acnes osteomyelitis: A retrospective analysis (2010) (32)
Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. (2002) (32)
Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial. (2019) (31)
Switching regimens in virologically suppressed HIV‐1‐infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)‐containing regimens (2016) (31)
Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1: Secondary Analysis of a Randomized Clinical Trial. (2016) (31)
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors. (2001) (31)
Neuropsychiatric Adverse Events after Switching from An Antiretroviral Regimen Containing Efavirenz without Tenofovir to An Efavirenz Regimen Containing Tenofovir: A Report of Nine Cases (2006) (31)
Penetration of foscarnet into cerebrospinal fluid of AIDS patients (1993) (30)
Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability (2012) (30)
Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. (2005) (30)
High prevalence of undiagnosed COPD in a cohort of HIV-infected smokers (2014) (30)
Challenges of controlling a large outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in a French university hospital. (2015) (30)
Challenges for the Clinical Development of New Nucleoside Reverse Transcriptase Inhibitors for HIV Infection (2005) (29)
Pyrimethamine plus azithromycin for treatment of acute toxoplasmic encephalitis in patients with AIDS (1993) (29)
Peripheral neuropathy during stavudine‐didanosine antiretroviral therapy (2001) (29)
Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review (2014) (28)
Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients (2005) (28)
Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study. (2002) (27)
Adverse Reactions to Cotrimoxazole in HIV-infected Patients: Predictive Factors and Subsequent HIV Disease Progression (2001) (27)
Virological and pharmacological factors associated with virological response to salvage therapy after an 8‐week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097) (2005) (27)
A multicentre prospective study for the polymerase chain reaction detection of Toxoplasma gondii DNA in blood samples from 186 AIDS patients with suspected toxoplasmic encephalitis. Bio-Toxo Study Group. (1997) (27)
Evaluation of the tuberculin skin test and the interferon-γ release assay for TB screening in French healthcare workers (2009) (27)
HIV-associated haemophagocytic syndrome (1990) (26)
Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRS143 randomised trial. (2021) (26)
An outbreak of airborne tularaemia in France, August 2004. (2006) (26)
A liquid chromatography-tandem mass spectrometry assay for quantification of rilpivirine and dolutegravir in human plasma. (2014) (26)
Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients (2014) (26)
Limited effectiveness of systematic screening by nasopharyngeal RT-PCR of medicalized nursing home staff after a first case of COVID-19 in a resident (2020) (25)
Nevirapine–Raltegravir Combination, An Nrti and Pi/R Sparing Regimen, as Maintenance Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients (2013) (25)
Prevalence and risk factors of sleep disturbances in a large HIV-infected adult population (2014) (25)
N-acetyl-β-D-Glucosaminidase (NAG) isoenzymes release from human monocyte-derived macrophages in response to zymosan and human recombinant interferon-γ (1991) (25)
[Value of I.N.R.A. brucellin for the diagnosis of human brucellosis. Institut National de la Recherche Agronomique]. (1984) (25)
Final analysis of the Trilège induction-maintenance trial: results at 18 months (2002) (24)
Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults (2007) (23)
Patterns of patient and healthcare provider viewpoints regarding participation in HIV cure-related clinical trials. Findings from a multicentre French survey using Q methodology (ANRS-APSEC) (2017) (23)
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. (2016) (23)
A highly virulent variant of HIV-1 circulating in the Netherlands (2022) (23)
Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients. (2017) (22)
Efficacy and safety of stavudine and didanosine combination therapy in antiretroviral‐experienced patients (1998) (22)
[Hemophagocytic syndromes. A series of 23 cases]. (1996) (22)
Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST (2007) (22)
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study. (2019) (22)
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial. (2018) (22)
Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial. (2010) (22)
[Extrapulmonary tuberculosis in the central western region. Retrospective study of 217 cases (Gericco 1991-1993)]. (1998) (21)
Legionella pneumophila Arthritis: use of medium specific for Mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens. (2002) (21)
Multiple choices for HIV therapy with integrase strand transfer inhibitors (2012) (21)
Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. (2005) (21)
Use of an Itraconazole/allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. (1995) (21)
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course (2017) (21)
Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. (2000) (21)
HIV is associated with airway obstruction: a matched controlled study (2017) (21)
Immediate Versus Deferred Switching From a Boosted Protease Inhibitor–based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study (2018) (21)
Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course (2017) (21)
High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial. (2020) (20)
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. (2014) (20)
Twelve-Year Experience of Nevirapine Use: Benefits and Convenience for Long-Term Management in a French Cohort of HIV-1–Infected Patients (2010) (20)
Efficacy of Nevirapine-Based HAART in HIV-1-Infected, Treatment-Naive Persons with High and Low Baseline Viral Loads (2001) (19)
The detection of non-adherence by self-administered questionnaires can be optimized by protease inhibitor plasma concentration determination. (2003) (19)
Tolerability of high-dose ceftriaxone in CNS infections: a prospective multicentre cohort study (2019) (19)
Acute co-infection with human immunodeficiency virus (HIV) and cytomegalovirus. (1990) (19)
Viremia Copy-Years as a Predictive Marker of All-Cause Mortality in HIV-1–Infected Patients Initiating a Protease Inhibitor–Containing Antiretroviral Treatment (2015) (18)
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs (2022) (18)
Incidence of diabetes in HIV-infected patients treated with first-line integrase strand transfer inhibitors: a French multicentre retrospective study. (2020) (17)
Drug resistance and tropism as markers of the dynamics of HIV-1 DNA quasispecies in blood cells of heavily pretreated patients who achieved sustained virological suppression. (2016) (17)
Non-tuberculous mycobacterial tenosynovitis (1990) (17)
Low alcohol consumption as a predictor of higher CD4+ cell count in HIV-treated patients: a french paradox or a proxy of healthy behaviors? The ANRS APROCO-COPILOTE CO-08 cohort. (2014) (17)
Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial (2019) (17)
Localized Mycobacterium genavense Soft Tissue Infection in an Immunodeficient HIV-Negative Patient (2000) (17)
Spontaneous rupture of the spleen revealing primary human immunodeficiency virus infection. (1997) (17)
Ludwig's angina: a diagnostic and surgical priority. (2020) (17)
Switch from Enfuvirtide to Raltegravir Lowers Plasma Concentrations of Darunavir and Tipranavir: a Pharmacokinetic Substudy of the EASIER-ANRS 138 Trial (2011) (17)
Pleural involvement in hairy cell leukemia response to recombinant interferon-alpha. (1990) (17)
Plea for multitargeted interventions for severe COVID-19 (2020) (17)
Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy. (2018) (16)
Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV‐1‐infected patients (2006) (16)
[Multifocal tuberculosis. Apropos of 49 cases in the midwest region. GERICCO (Group for Epidemiology and Research in Clinical Infections of the Central West of France), 1991-1993]. (1998) (16)
[Epidemiology of candidemia: a one-year prospective observational study in the west of France]. (2009) (16)
Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1 (2018) (16)
Acceptability of HIV cure-related trials: the challenges for physicians and people living with HIV (ANRS-APSEC) (2018) (16)
Doravirine dose Selection and 96-Week Safety and Efficacy versus Efavirenz in Antiretroviral Therapy-Naive Adults with HIV-1 Infection in a Phase IIb Trial (2019) (16)
Correction of myelotoxicity after switch of linezolid to tedizolid for prolonged treatments (2017) (15)
Brief Report: Prolonged Viral Suppression Over a 12-Year Follow-up of HIV-Infected Patients The Persistent Impact of Adherence at 4 Months After Initiation of Combined Antiretroviral Therapy in the ANRS CO8 APROCO-COPILOTE Cohort (2016) (15)
Efficacy and Safety of an NRTI-Sparing Dual Regimen of Raltegravir and Ritonavir-Boosted Protease Inhibitor in a Triple Antiretroviral Class-Experienced Population (2009) (15)
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination. (2016) (15)
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised (2019) (15)
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. (2005) (15)
Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort (2005) (15)
Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo) (2012) (15)
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV‐infected adults on a long‐term non‐nucleoside reverse transcriptase inhibitor‐based regimen (2013) (14)
Severe Symptomatic Primary Human Cytomegalovirus Infection despite Effective Innate and Adaptive Immune Responses (2016) (14)
Role and evolution of viral tropism in patients with advanced HIV disease receiving intensified initial regimen in the ANRS 130 APOLLO trial. (2013) (14)
An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains (2017) (14)
Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy. (2011) (14)
Effect of Lopinavir/Ritonavir Monotherapy on Quality of Life and Self-Reported Symptoms among Antiretroviral-Naive Patients: Results of the MONARK Trial (2008) (14)
CD4 T cell recovery is slower in patients experiencing viral load rebounds during HAART (2001) (14)
Practice guidelines for acute bacterial meningitidis (except newborn and nosocomial meningitis). (2009) (14)
Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial) (2006) (14)
Randomized Placebo-Controlled Study of the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of 10-Day Monotherapy With BMS-986001, a Novel HIV NRTI, in Treatment-Experienced HIV-1–Infected Subjects (2013) (13)
Antiviral drugs in hospitalized patients with COVID-19 - the DisCoVeRy trial (2021) (13)
Genotypic Resistance Analysis of the Virological Response to Fosamprenavir-Ritonavir in Protease Inhibitor-Experienced Patients in CONTEXT and TRIAD Clinical Trials (2008) (13)
Prevalence and Predictors of Deterioration of a Trustful Patient-Provider Relationship Among HIV-Infected Persons Treated With Antiretroviral Therapy (2008) (13)
Evaluation of the acceptability in France of the vaccine against papillomavirus (HPV) among middle and high school students and their parents (2020) (13)
Apoptosis characterizes immunological failure of HIV infected patients (2009) (13)
Association of Apolipoproteins C3 and E with Metabolic Changes in HIV-Infected Adults Treated with a Protease-Inhibitor-Containing Antiretroviral Therapy (2005) (13)
[Clinical and bacteriological aspects of nocardiasis. 9 cases]. (1995) (12)
Reactive haemophagocytic syndrome in AIDS. (1996) (12)
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen (2017) (12)
Ritonavir-Saquinavir Dual Protease Inhibitor Compared to Ritonavir Alone in Human Immunodeficiency Virus-Infected Patients (2001) (12)
Efficacy, safety and patient‐reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor‐experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study) (2018) (12)
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients (2005) (12)
Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV‐infected patients: a population approach (2009) (12)
Hematogenous anaerobic vertebral osteomyelitis due to Bacteroides fragilis in a diabetic patient. (2003) (12)
Impact of immunodepression and moderate alcohol consumption on coronary and other arterial disease events in an 11-year cohort of HIV-infected patients on antiretroviral therapy (2012) (12)
Long-term outcome of patients with non-operated prosthetic valve infective endocarditis: is relapse the main issue? (2019) (12)
Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen (2018) (11)
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial (2021) (11)
Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults (2015) (11)
Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/ Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial (2019) (11)
Long‐term assessment of nevirapine‐containing highly active antiretroviral therapy in antiretroviral‐naive HIV‐infected patients: 3‐year follow‐up of the VIRGO study (2006) (11)
Diabetes and dyslipidaemia are associated with oxidative stress independently of inflammation in long-term antiretroviral-treated HIV-infected patients. (2019) (11)
Adherence to and Effectiveness of Highly Active Antiretroviral Treatment for HIV Infection: Assessing the Bidirectional Relationship (2012) (11)
Specific anti-toxoplasmic IgG antibody immunoblot profiles in patients with AIDS-associated Toxoplasma encephalitis. (1999) (11)
Differences in HIV cure clinical trial preferences of French people living with HIV and physicians in the ANRS‐APSEC study: a discrete choice experiment (2020) (11)
Pre-exposure prophylaxis: a useful tool to prevent human immunodeficiency virus infection? (2016) (11)
Pasteurella multocida appendiceal peritonitis: report of three cases and review of the literature (1986) (11)
Plasma Levels of Indinavir and Nelfinavir at Time of Virologic Response May Have a Different Impact on the Risk of Further Virologic Failure in HIV-Infected Patients (2003) (10)
Salvage Therapy with Ritonavir-Boosted Amprenavir/Fosamprenavir: Virological and Immunological Response in Two Years Follow-up (2005) (10)
Cryptosporidiosis and microsporidiosis as causes of diarrhea in kidney and/or pancreas transplant recipients. (2020) (10)
Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. (2015) (10)
Early diagnosis and risk factors of acute hepatitis C in high-risk MSM on preexposure prophylaxis. (2020) (10)
Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. (1995) (10)
Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine (1999) (10)
Antiretroviral treatment French guidelines 2013: economics influencing science. (2014) (10)
[Neuromeningeal listeriosis in adults, excluding pregnancy. Prognosis and development of neurologic manifestations. Retrospective study of 63 cases]. (1987) (10)
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study (2016) (10)
Reaching the Second and Third Joint United Nations Programme on HIV/AIDS 90-90-90 Targets Is Accompanied by a Dramatic Reduction in Primary Human Immunodeficiency Virus (HIV) Infection and in Recent HIV Infections in a Large French Nationwide HIV Cohort. (2020) (10)
Maladie de Still de l’adulte avec syndrome d’activation macrophagique: Intérêt de la ciclosporine (2005) (10)
[Abiotrophia related endocarditis: contribution of molecular biology]. (1999) (10)
MIKADO: a multicentre, open‐label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine (2001) (10)
[Mycoplasma pneumoniae infections. A multicenter retrospective study of 182 cases]. (1988) (10)
Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate – emtricitabine for HIV pre‐exposure prophylaxis (2020) (10)
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group (2022) (9)
The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults (2016) (9)
Host and disease factors are associated with cognitive function in European HIV‐infected adults prior to initiation of antiretroviral therapy (2016) (9)
Developing a patient-reported outcome measure for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through qualitative analysis (2018) (9)
Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study Group. (2000) (9)
Despite an impaired response to IL-7, T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI (2011) (9)
How do HIV-infected smokers react to cigarette price increases? Evidence from the APROCO-COPILOTE-ANRS CO8 Cohort. (2009) (9)
Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study (2021) (9)
HCV-Related Mortality Among HIV/HCV Co-infected Patients: The Importance of Behaviors in the HCV Cure Era (ANRS CO13 HEPAVIH Cohort) (2019) (9)
Characteristics and outcome of multidrug-resistant tuberculosis in a low-incidence area. (2018) (9)
Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat’AIDS cohort (2019) (9)
Endocarditis caused by Neisseria elongata subspecies nitroreducens: case report and literature review. (1993) (9)
No Significant Influence of Saquinavir Hard-Gel Capsule Administration on Pharmacokinetics of Lopinavir in Combination With Ritonavir: A Population Approach (2005) (9)
Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort. (2012) (8)
Triple nucleoside reverse transcriptase inhibitor‐ vs. nonnucleoside reverse transcriptase inhibitor‐containing regimens as first‐line therapy: efficacy and durability in a prospective cohort of French HIV‐infected patients (2005) (8)
Evolocumab in HIV-Infected Patients With Dyslipidemia (2020) (8)
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study (2018) (8)
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study (2018) (8)
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA (2002) (8)
Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. (2019) (8)
Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study. (2021) (8)
A simple high performance liquid chromatography assay for monitoring plasma concentrations of tipranavir in HIV infected patients. (2006) (8)
The spectrum of HIV mother-to-child transmission risk (2014) (8)
Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir–Ritonavir Plus Either Raltegravir or Tenofovir–Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial (2017) (8)
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study (2019) (8)
Mathematical modeling of HIV dynamics after antiretroviral therapy initiation: a clinical research study. (2014) (8)
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen. (2013) (7)
Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study (2019) (7)
Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH). (2020) (7)
XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants (2021) (7)
[Community-acquired bacterial meningitis in the Loire-Atlantic region: evolution of pneumococcal and meningococcal sensitivity to penicillin]. (1999) (7)
R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen (2003) (7)
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. (2021) (7)
Renal dysfunction in adults during measles. (2015) (7)
[Measles in the Nantes Teaching Hospital during the 2008-2009 epidemic]. (2011) (7)
[Adult-onset Still disease with hemophagocytic syndrome treated with cyclosporine]. (2005) (7)
Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study. (2012) (7)
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients. (2009) (7)
Progression to AIDS or Death as Endpoints in HIV Clinical Trials (2001) (7)
Risk of diabetes in HIV‐infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort (2018) (7)
Kaposi sarcoma among people living with HIV in the French DAT’AIDS cohort between 2010 and 2015 (2020) (7)
Teaching individualized antibiotic dosage regimens by means of two computer-assisted learning programs. (1994) (7)
Microelimination or not? The changing epidemiology of HIV-HCV coinfection in France 2012-2018. (2021) (6)
Diabetic foot ulcers: epidemiology and physiopathology. (2000) (6)
N-acetyl-beta-D-glucosaminidase (NAG) isoenzymes release from human monocyte-derived macrophages in response to zymosan and human recombinant interferon-gamma. (1991) (6)
Multimorbidity in Elderly Subjects according to the year of diagnosis of HIV-Infection - A Cross-Sectional DATAIDS Cohort Study. (2019) (6)
Acceptance of pregnant women's vaccination against pertussis among French women and health professionals: PREVACOQ-1 and -2 studies. (2019) (6)
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial). (2020) (6)
HIV-infected patients aged above 75years. (2020) (6)
18th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV. (2016) (6)
Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV. (2019) (6)
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team. (1998) (6)
Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. (2009) (6)
Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19 (2022) (6)
[Hematogenic bacterial endophthalmitis. A rare infection with very poor functional prognosis]. (1996) (6)
Short communication: Paraoxonase 1 (PON1) in French HIV-infected patients under antiretroviral therapy: relationship with the metabolic syndrome and inflammation. (2013) (6)
Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen. (2019) (6)
Enhanced immunovirological response in women compared to men after antiretroviral therapy initiation during acute and early HIV‐1 infection: results from a longitudinal study in the French ANRS Primo cohort (2020) (6)
[Infected aneurysms of the aorta]. (1991) (5)
10th Conference on Retroviruses and Opportunistic Infections 2003 Boston, USA (2003) (5)
["Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors]. (1999) (5)
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight) (2018) (5)
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis (2022) (5)
Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight) (2018) (5)
Patient profiles as organizing HIV clinicians’ ART adherence management: a qualitative analysis (2018) (5)
Factors associated with the level of CD4 cell counts at HIV diagnosis in a French cohort: a quantile regression approach (2017) (5)
8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial (2018) (5)
Changes in Sexual Behaviors in Men Who Have Sex with Men: A Comparison Between the Double-Blind and Open-Label Extension Phases of the ANRS-IPERGAY Trial (2020) (5)
[Pulmonary hypertension in HIV-infected patients]. (2001) (5)
[Value of immunoglobulins in Schulman fasciitis]. (2000) (5)
[Contribution of molecular biology and Aspergillus galactomannan antigen assay for the diagnosis of histoplasmosis]. (2010) (5)
Early diagnosis and risk factors of acute hepatitis c in high-risk men who have sex with men on pre-exposure prophylaxis. (2019) (5)
Effect of On-Demand Oral Pre-exposure Prophylaxis With Tenofovir/Emtricitabine on Herpes Simplex Virus-1/2 Incidence Among Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Trial (2018) (5)
Long-term efficacy and safety of etravirine-containing regimens in a real-life cohort of treatment-experienced HIV-1-infected patients (2016) (5)
Information That Should Be Given to HIV Cohort Participants during Ongoing Research: The Viewpoints of Patient Representatives and Research Professionals (2011) (5)
Mean cost of a first combination antiretroviral therapy in HIV-infected patients in France, and determinants of expensive drugs prescription (2012) (5)
[Unusual lung mycosis: Penicillium++ marneffei infection]. (1998) (5)
[Health related quality of life and lipodystrophy syndrome among HIV-infected patients]. (2006) (5)
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis. (2020) (5)
Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir (2018) (5)
[Skin and osteoarticular bacterial infections of the diabetic foot. Ulcers of the diabetic foot: epidemiology and physiopathology]. (2000) (5)
Erratum: Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: Results from an inter-cohort analysis (Antiviral Therapy (2006) 11 (657-674)) (2006) (5)
Smoking‐associated morbidities on computed tomography lung cancer screens in HIV‐infected smokers (2017) (5)
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. (2021) (4)
[Cutaneous Cytomegalovirus ulceration in AIDS: diagnosis by in situ hybridization and response to treatment]. (1992) (4)
[Mortality rate of HIV-infected adults compared with the general population: long-term and CD4-lymphocyte-dependent results]. (2008) (4)
XAV-19, a novel swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike, efficiently neutralizes B.1.1.7 British and B.1.351 South-African variants (2021) (4)
Community-Based Care in the ANRS-IPERGAY Trial: The Challenges of Combination Prevention. (2019) (4)
[Infected arterial aneurysms. Anatomo-clinical and surgical aspects apropos of 12 cases]. (1986) (4)
Atherosclerotic Cardiovascular Events in Patients Infected With Human Immunodeficiency Virus and Hepatitis C Virus. (2020) (4)
Analyzing Plasma HIV-1 RNA Measurements as Multiple Recurrent Events in Clinical Trials (2006) (4)
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy (2016) (4)
[Skin and osteoarticular infections of the diabetic foot. Role of infection]. (2000) (4)
Determinants of blood telomere length in antiretroviral treatment‐naïve HIV‐positive participants enrolled in the NEAT 001/ANRS 143 clinical trial (2019) (4)
Microangiopathies thrombotiques au cours de l'infection à VIH: quatre observations (1996) (4)
[Secondary prophylaxis for herpes zoster wi oral acyclovir in HIV patients]. (1999) (4)
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients. (1999) (4)
Assessment of drug–drug interaction in an elderly human immunodeficiency virus population: Comparison of 3 expert databases (2020) (4)
Discussing HIV Status: Is It Easier After 10 Years of Antiretroviral Treatment? The ANRS CO8 APROCO-COPILOTE Cohort (2016) (4)
[Pleuropulmonary disease caused by Pasteurella multocida. Study of 9 cases. Review of the literature]. (1986) (4)
Lack of benefit of 3‐month intensification with enfuvirtide plus optimized background regimen (OBR) versus OBR alone in patients with multiple therapeutic failures: The INNOVE study (2012) (4)
Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study (2019) (4)
Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1–positive individuals (2020) (4)
Sub-Saharan African migrants have slower initial CD4+ cell recovery after combined antiretroviral treatment initiation than French natives. (2017) (4)
[Skin and osteoarticular bacterial infections of the diabetic foot. Treatment]. (2000) (4)
Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection* (2016) (4)
[Clinical efficacy and tolerance of enfuvirtide (Fuzeon), new antiretroviral inhibitors of intracellular penetration of human immunodeficiency virus (HIV) type 1]. (2004) (4)
ThoracicSalmonella typhimurium abscess in an AIDS patient (2005) (4)
[Resistance to protease inhibitors: the role of the MDR gene]. (2000) (3)
[Cytomegalovirus infections in AIDS]. (1995) (3)
Factors associated with being overweight and obesity in people living with HIV on antiretroviral therapy : socio-clinical, inflammation, and metabolic markers. (2021) (3)
Endocarditis caused byNeisseria elongata subspeciesnitroreducens: Case report and literature review (1993) (3)
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients. (2013) (3)
Prevalence of Mycoplasma genitalium Infection and Relationship with Symptoms Among Adults Attending a Sexual Health Centre. (2017) (3)
Changes in Cognitive Function over 96 Weeks after Initiating Darunavir/Ritonavir with Either Raltegravir or Tenofovir-Emtricitabine: NEAT 001 / ANRS 143 Randomised Controlled Study (2015) (3)
TOXOPLASMOSE CEREBRALE CONTEMPORAINE D'UNE PRIMO-INFECTION TOXOPLASMIQUE AU COURS DU SIDA (1992) (3)
Impact of Education and Support on the Tolerability and Quality of Life in a Cohort of HIV-1 Infected Patients Treated With Enfuvirtide (SURCOUF Study) (2008) (3)
[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February]. (1996) (3)
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity. (2008) (3)
Itraconazole oral solution for treatment of fluconazole resistant oral/esophageal candidosis in HIV-infected patients : Results of a prospective multicenter study. I. Clinical assessment (2008) (3)
Rapid emergence of meningococci with reduced susceptibility to penicillin in France: the need for vigilance in meningitis treatment. (1998) (3)
Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen. (2014) (3)
Fibronectin in HIV-infected patients: a prospective study. (1992) (3)
Virological response to darunavir in patients infected with HIV is linked to darunavir resistance–associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters (2012) (3)
Evolution of plasma hepatitis C virus load in patients coinfected by HIV and hepatitis C Virus started on a protease inhibitor-containing antiretroviral regimen, Agence Nationale de Recherches sur le SIDA CO8 APROCO-COPILOTE cohort. (2008) (3)
Anti-gp41 antibody levels reflect HIV viral suppression and cellular reservoir in long-term antiretroviral-treated trial participants (2019) (3)
Factors associated with psoriasis in a French Nationwide HIV cohort: the independent role of HLA-B*57: 01. (2020) (3)
Developmental delay and behavioral disorders in 59 HIV-exposed uninfected infants. (2017) (3)
Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997 – 1999 , ANRS CO 8 APROCO-COPILOTE (2009) (3)
Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis (2021) (2)
Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines. (2010) (2)
[The Nadis cohort: 6236 HIV-infected patients followed up in French university hospitals]. (2005) (2)
Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial (2022) (2)
Human Immunodeficiency Virus Type 1 Group O Infection in France: Clinical Features and Immunovirological Response to Antiretrovirals (2018) (2)
[Legionnaires' disease with agranulocytosis of favorable course]. (1988) (2)
[Update on consensual proposals (1993 February). Role of cotrimoxazole in the primary prevention of toxoplasmosis in patients with HIV infection]. (1993) (2)
An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial (2022) (2)
Disturbance of apolipoprotein B100 containing lipoprotein metabolism in severe hyperlipidemic and lipodystrophic HIV patients on combined antiretroviral therapy: evidences of insulin resistance effect. (2008) (2)
Rate of DRESS Syndrome With Raltegravir and Role of the HLA-B*53: 01 Allele. (2020) (2)
Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort (2012) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
MAXIMIZING THE EFFECTIVENESS OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY : IS THERE A ROLE FOR QUADRUPLE REGIMENS ? (2002) (2)
The Immune Response to the RT181-189 Epitope in HIV-1-Infected Patients is Associated with Viral Sequence Polymorphism Flanking the Epitope (2011) (2)
International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
Measles seroprevalence in human immunodeficiency virus-infected adults born in the era of measles vaccination (2022) (2)
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial (2018) (2)
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease. (2020) (2)
[Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency]. (2000) (2)
Remdesivir for the Treatment of Hospitalised Patients with COVID-19 (DisCoVeRy): A Randomised, Controlled, Open-Label Trial (2021) (2)
[Varicella zoster virus infection area in 39 HIV-infected patients. Therapeutic management]. (1999) (2)
Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV/HCV-coinfected patients- ANRS-CO13 HEPAVIH cohort (2018) (2)
[Plasma fibronectin in patients with bronchopulmonary cancer]. (1983) (2)
Sub-Saharan Africa migrants have slower initial CD4 cell recovery after cART initiation than French natives, regardless of living conditions. (2017) (2)
Immune reconstitution inflammatory syndrome presenting as secondary syphilis with polymorphous erythema and knee arthritis (2017) (2)
[Cerebral toxoplasmosis concomitant with primary toxoplasma infection in AIDS]. (1992) (2)
[Aphthous hepatic lesions and Behçet syndrome]. (1982) (2)
Virus-Associated Nephropathies: A Narrative Review (2022) (2)
Changes in Bone Mineral Density (BMD) over 96 Weeks on Darunavir/Ritonavir (DRV/r) + Raltegravir (RAL) or DRV/r + Tenofovir/Emtricitabine (TDF/FTC) (2014) (2)
Is long‐term virological response related to CCR5 Δ32 deletion in HIV‐1‐infected patients started on highly active antiretroviral therapy? (2010) (2)
Impact of nevirapine or efavirenz co‐administration on ritonavir‐boosted amprenavir pharmacokinetics in HIV‐infected patients (2008) (2)
Thrombocytopenia during primary HIV-1 infection predicts the risk of recurrence during chronic infection. (2012) (2)
Risk factors for HIV infection among men who have sex with men in the ANRS IPERGAY PrEP trial (2021) (2)
Epidemiology and clinical impact of respiratory co-infections at diagnosis of Pneumocystis jirovecii Pneumonia. (2021) (2)
[Major hyperferritinemia in Still disease in adults]. (1994) (2)
False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers. (2019) (1)
Prophylaxie antibiotique en chirurgie digestive pediatrique (1989) (1)
Raltegravir 1200 mg once daily as maintenance therapy in virologically suppressed HIV-1 infected adults: QDISS open-label trial (2021) (1)
Multiple choices for HIV therapy with integrase strand transfer inhibitors (2012) (1)
Ledipasvir/Sofosbuvir in NS3/4A Protease Inhibitor-Experienced Subjects with HCV Genotype 1 and HIV-Co-Infection Final Results of the ANRS HC31 Softrih Study (2016) (1)
Previously unreported emergence of A265V substitution in the integrase gene in association with bictegravir virological failure. (2020) (1)
[Experience with nevirapine taken once daily in 93 HIV-infected patients]. (1999) (1)
Combined Bacterial Meningitis and Infective Endocarditis: When Should We Search for the Other When Either One is Diagnosed? (2022) (1)
[Thrombotic microangiopathies in HIV infection: 4 cases]. (1996) (1)
Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron) (2022) (1)
[Septic arthritis caused by Pasteurella multocida. Treatment with a fluoroquinolone]. (1989) (1)
Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART (2006) (1)
Increased risk of severe COVID-19 in hospitalized patients with SARS-CoV-2 Alpha variant infection: a multicentre matched cohort study (2022) (1)
[Risk factors of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention]. (1996) (1)
Pharmacokinetics (PK) of darunavir/ritonavir (DRV/RTV) with tenofovir DF/emtricitabine (TDF/FTC) or raltegravir (RAL) in HIV-infected adults enrolled in the NEAT001/ANRS143 study and relationship with virological response (2016) (1)
Infection à parvovirus et grossesse (1990) (1)
Measles resurgence: a retrospective analysis of 55 cases (2011) (1)
Releasing the true power of protease inhibitors (2003) (1)
[Skin and osteoarticular bacterial infections in the diabetic foot. The need for multidisciplinary management]. (2000) (1)
[Anti-HIV drugs]. (1999) (1)
P017: Low virologic failure on TDF/FTC/RPV in HIV-infected naïve and virologically suppressed patients with strict clinical selection and/or DNA genotyping (2015) (1)
One-Year Sequelae and Quality of Life in Adults with Meningococcal Meningitis: Lessons from the COMBAT Multicentre Prospective Study (2022) (1)
HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data) (2022) (1)
Correction: An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy (2016) (1)
Pyomyosite aigue a staphylocoque dore: Une observation (1988) (1)
Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials (2022) (1)
[Acute monoblastic leukemia in non-Hodgkin's malignant lymphoma treated with prednimustine]. (1989) (1)
[Enfuvirtide, first fusion inhibitor in the treatment of human immunodeficiency virus infection: mechanism of action and pharmacokinetics]. (2004) (1)
Characteristics and Outcome of HIV Associated Classical Hodgkin's Lymphoma Among 68 Patients Included in the French ANRS CO16 Lymphovir Cohort Study (2014) (1)
Optimisation de l’efficacité des inhibiteurs de protéase par « boosting » (2003) (1)
Clinical and Epidemiologic Characteristics and Therapeutic Management of Patients with Vibrio Infections, Bay of Biscay, France, 2001–2019 (2022) (1)
[Severe hypercalcemia in a patient treated with fluconazole and rifampicin]. (1998) (1)
No barrier to care, yet disparities in the HIV care continuum in France: a nationwide population study. (2021) (1)
Bronchite aiguë et surinfection de bronchite chronique. L'azithromycine, son efficacité en situation quotidienne (1996) (1)
Value of intravenous gamma globulins at heavy dose in thrombopenia in a case of leptospirosis (1988) (1)
[Lyme neuroborreliosis of mental manifestation. Apropos of a case]. (1996) (1)
Pseudomonas aeruginosa sepsis presenting as peripheral subcutaneous nodules. Report of 2 cases (2004) (1)
Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis (2005) (1)
Clinical relevance of the interaction when switching non-nucleoside reverse transcriptase inhibitors in patients infected with HIV. (2014) (1)
[Outcome of HIV-infected patients after 5 years of antiretroviral therapy including a protease inhibitor: the Aproco/Copilote Cohort]. (2005) (1)
Influence of HLA‐C environment on the spontaneous clearance of hepatitis C in European HIV–HCV co‐infected individuals (2020) (1)
Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study). (2007) (1)
Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort (2014) (1)
Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial). (2020) (1)
Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort (2022) (1)
Acceptance rate of clinical study endpoints and adequacy of source documentation: experience from clinical study endpoint review in NEAT001/ANRS143 (2014) (1)
Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study-authors' response. (2020) (1)
Q-FEVER ENDOCARDITIS (1989) (1)
[Lipo-atrophy of the buttocks after intramuscular injection of adrenal cortex hormones]. (1991) (1)
Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients. (2016) (1)
Decreased darunavir concentrations during once-daily co-administration with maraviroc and raltegravir: OPTIPRIM-ANRS 147 trial (2018) (1)
[Paralysis of the 3d cranial nerve disclosing primary cytomegalovirus infection in an immunocompetent adult]. (1995) (1)
HIV Drug Therapy in the Americas 16–18 April 2015, Mexico City, Mexico (2015) (0)
Editorial 44.pmd (2005) (0)
[Erythroblastopenia secondary to zidovudine]. (1998) (0)
Hepatitis A and B vaccine uptake and immunisation among men who have sex with men seeking PrEP: a substudy of the ANRS IPERGAY trial (2022) (0)
POTENCY AND ADHERENCE : IMPROVING HAART EFFICACY IN THE CLINIC * — (2002) (0)
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag‐specific cellular immune response (2014) (0)
A-10 Cryptococcose neuro-mninge des patients non-infects par le VIH (2004) (0)
Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeﬁciency Virus–Infected Patients (2002) (0)
The burden of hospitalisations for COVID-19 in France: a study of all cases in the national insurance claims database in 2020 (2023) (0)
Track B Clinical Science (2012) (0)
PIN1 PHARMACEUTICAL MANAGEMENT OF NEWLY HIV + DIAGNOSED PATIENTS: RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT (2003) (0)
[Inoculation meningitis at Streptococcus mitis]. (1988) (0)
Nevirapine use is associated with higher bone mineral density in HIV-I positive patients on long-term antiretroviral therapy. (2019) (0)
PMU136 PSYCHOMETRIC PROPERTIES OF MALE SEXUAL HEALTH QUESTIONNAIRE (MSHQ), IN HIV AND HCV PATIENTS (2019) (0)
[Antibody-dependent cell-mediated cytotoxicity: a method of predicting the severity of fetomaternal alloimmunization in the Rhesus system? A retrospective study of 32 cases]. (1985) (0)
Limited weight impact after switching from boosted protease inhibitors to dolutegravir in persons with HIV with high cardiovascular risk: a post hoc analysis of the 96-week NEAT-022 randomized trial. (2022) (0)
[Cerebro-meningeal infections in patients with human immunodeficiency virus infections]. (1994) (0)
530 ALT increase after initiation of protease inhibitor (PI) containing antiretroviral therapy in HIV-HCV coinfected patients is not related to high PI plasma concentrations. ANRSCO-08 cohort (2006) (0)
well as endothelial cell dysfunction and acute vasculitis (2). In our patient's case, lymphoid infiltration of trabecular veins was References (1997) (0)
Prevalence and incidence of HEV among men using HIV pre-exposure prophylaxis: A sub-study of the ANRS IPERGAY trial. (2023) (0)
Cytokine profiles in adults with imported malaria: insights from the PALUREA cohort study (2022) (0)
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial (2018) (0)
H anaerobic vertebral osteomyelitis due to Bacteroides fragilis in a diabetic patient (2003) (0)
[Can antiretroviral treatment eradicate Prurigo nodularis in HIV infected patients?]. (2009) (0)
[Primary effusion lymphoma: a rare form of lymphoma associated with herpesvirus 8 in AIDS]. (1999) (0)
[Bioterrorism: are we ready for bacteriological warfare]. (2003) (0)
Short-course intensification with enfuvirtide in virologic failure: impact on intracellular HIV reservoir and on viral tropism (INNOVE study) (2010) (0)
[The Strep-test in the diagnosis of pharyngitis]. (1998) (0)
[Severe and early hypercalcemia in rhabdomyolysis]. (1990) (0)
[Consensual proposals for the treatment of toxoplasmosis in patients with human immunodeficiency virus infection]. (1993) (0)
Listeria Endophthalmitis Cured With Linezolid in an Immunocompetent Farmer Woman: Hazard of a Sweep of a Cow’s Tail (2019) (0)
[Septic Campylobacter fetus thrombophlebitis: a new case]. (1993) (0)
UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV (2004) (0)
Cannabis Use and Plasma Human Immunodeficiency Virus (HIV) RNA Levels in Patients Coinfected With HIV and Hepatitis C Virus Receiving Antiretroviral Therapy: Data From the ANRS CO13 HEPAVIH Cohort (2020) (0)
Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants (2023) (0)
[Prophylactic antibiotic therapy in surgery: applications in digestive surgery]. (1986) (0)
Long-term neuro-functional disability in adult patients with community-acquired bacterial meningitis (2022) (0)
[Empirical treatment of febrile episodes in granulocytopenic patients with a combination of piperacillin and ofloxacin. Preliminary study]. (1990) (0)
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen. (2020) (0)
Characteristics and Outcome Among 116 Patients with HIV Associated Lymphoma Included in the French ANRS CO16 Lymphovir Cohort Study. (2012) (0)
Evaluation of drug abuse by hair analysis and self-reported use among MSM under PrEP: Results from a French sub-study of the ANRS-IPERGAY trial. (2020) (0)
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study). (2018) (0)
[Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort]. (2007) (0)
Antiretroviral therapy with integrase inhibitors: more options. (2013) (0)
Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH) (2022) (0)
Randomized Multicenter Trial ( ANRS 130 Immunological Response : Results of a Immunosuppression Does Not Improve HIV-1-Infected Patients with Severe through Addition of Enfuvirtide in Naive Intensification of Antiretroviral Therapy (2013) (0)
Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors (2022) (0)
Antiretroviral resistance at virologic failure in the NEAT 001 / ANRS 143 trial : Raltegravir + 1 Darunavir / ritonavir or Tenofovir / Emtricitabine + Darunavir / ritonavir as first line 2 antiretroviral therapy 3 (2016) (0)
Antibiothérapie prophylactique en chirurgie: applications à la chirurgie digestive (1986) (0)
Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study-authors' response. (2019) (0)
Hazard of a Sweep of a Cow Tail: Listeria Endophthalmitis in an Immunocompetent Farmer Woman, Treated with Linezolid (2018) (0)
Rate of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome with raltegravir and role of the HLA-B*53: 01 allele. (2020) (0)
Raltegravir becomes a once daily antiretroviral. (2017) (0)
Antibiotherapy of respiratory infections : short-term regimen versus long-term regimen (2008) (0)
[Febrile purpura disclosing primary cytomegalovirus infection]. (1990) (0)
Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study (2022) (0)
Five-year follow-up of patients enrolled in the NEAT 001/ANRS 143 randomized clinical trial: NEAT 001/ANRS 143 LONG TERM study. (2020) (0)
Effect of HIV infection and antiretroviral therapy initiation on genome-wide DNA methylation patterns (2023) (0)
EPH64 Public Health Impact of COVID-19 in French Ambulatory Patients With at Least One Risk Factor for Severe Disease (2022) (0)
[Isolated cough disclosing typhoid fever]. (1997) (0)
Once‐daily darunavir/ritonavir 400/100 mg in triple therapy: efficacy and penetration in seminal compartment in ANRS‐165 DARULIGHT study (2018) (0)
Antidepressant treatment associated with antiretroviral medications: The significant contribution of the pharmacist in consultation-liaison psychiatry (2015) (0)
[Conservative treatment of a hip prosthesis infection due to methicillin-resistant Staphylococcus aureus using prolonged antibiotic therapy based on linezolid followed by daptomycin]. (2008) (0)
536. Clinical Outcomes of Hospitalized COVID-19 Patients Treated with Remdesivir-NEAT ID 909REM Study (2021) (0)
[Chickenpox and herpes zoster. Epidemiology, physiopathology, diagnosis, development, treatment]. (1993) (0)
[Limitations of the protein profile for diagnostic orientation in initial internal medicine consultation. Prospective study on 76 patients]. (1997) (0)
UvA-DARE ( Digital Academic Repository ) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1 (2017) (0)
[Future prospects of valacyclovir in treating and preventing herpesviridae infections in immunosuppressed patients]. (1997) (0)
EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database (2022) (0)
PIN13: CHANGES IN ANTIRETROVIRAL (ARV) REGIMENS IN CLINICAL PRACTICE: RESULTS FROM THE STAR (SCHEMAS THERAPEUTIQUESANTIRETROVIRAUX) COHORT (2003) (0)
[Anemia of central origin and complement activation during Mycoplasma pneumoniae infection]. (1990) (0)
Les injections dues à Pasteurella multocida (1987) (0)
[Polynuclear neutrophils meningitis disclosing Mycoplasma pneumoniae infection]. (1996) (0)
[Therapeutic indications, antiretroviral treatment optimization and quality of life of patients taking enfuvirtide]. (2004) (0)
P18-01. Exquisite specificity of CTL response to the M184V mutation (2009) (0)
Monoclonal Antibodies in Hospitalised Patients with COVID-19: The Role of SARS-COV-2 Serostatus in an Evolving Pandemic (2023) (0)
Public health impact of COVID-19 in French ambulatory patients with at least one risk factor for severe disease (2022) (0)
Dramatic decline in new HIV diagnoses in persons born in France in a large nationwide HIV cohort. (2021) (0)
[Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine]. (2001) (0)
[Antibiotic sensitivity test: contribution to diagnosis, therapy and epidemiology. Travail du comité interface SFBC-SFRL]. (1997) (0)
[Meningitis with direct negative bacteriological examination. Prospective assessment of a decision making tree]. (2004) (0)
A propos d'un “audit”sur le fluconazole: l'avis de l'infectiologue (1998) (0)
Optimized Antiretroviral Therapy with Darunavir/Ritonavir, Etravirine and/or Raltegarvir: A Salvage Therapy Option in HIV-1 Infected Patients with Long-Term Therapeutic Failures, about 23 Cases (2012) (0)
[Therapeutic strategies for HIV infection: redefining simplification]. (2004) (0)
Influence of HLA-C environment on the spontaneous clearance of hepatitis C in European HIV-HCV co-infected individuals (2020) (0)
MENINGITE A POLYNUCLEAIRES NEUTROPHILES REVELANT UNE INFECTION A MYCOPLASMA PNEUMONIAE (1996) (0)
Torulopsis glabrata septicaemia as the first manifestation of a colonic tumour. (1990) (0)
Factors associated with non-AIDS-defining cancers and non HCV-liver related cancers in HIV / HCV-coinfected patients-ANRS-CO 13 HEPAVIH cohort (2019) (0)
L'infection staphylococcique chez l'adulte immunodéprimé (1986) (0)
[Diabetes mellitus and infections]. (1989) (0)
Neutrophil gelatinase-associated lipocalin , a marker of tubular dysfunction , is not increased in long-term virologically controlled patients receiving a tenofovir / emtricitabine 1 nevirapine regimen (2013) (0)
Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to ﬁrst-line antiretroviral regimen. (2017) (0)
[Guillain-Barré syndrome in Horton disease]. (1994) (0)
Influence of the ARV regimen on the early changes in plasma HIV RNA and immune activation at initiation of antiretroviral therapy in naïve HIV-1-infected patients. (2020) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Franc¸ois Raffi?

Franc¸ois Raffi is affiliated with the following schools:

University of Nantes

Franc¸ois Raffi's Academic­Influence.com Rankings

Why Is Franc¸ois Raffi Influential?

Franc¸ois Raffi's Published Works

Published Works

What Schools Are Affiliated With Franc¸ois Raffi?

Franc¸ois Raffi's AcademicInfluence.com Rankings